|
Dr. Chan joined ArQule in December 2005 as vice president pharmacology and toxicology. He was promoted to his current position in January 2007 and manages all research activities and new oncology drug candidate selection at ArQule. He is also responsible for toxicology and clinical pharmacology of the Company's drug candidates currently in human clinical trials. Dr. Chan was previously at MacroChem Corporation from 2001 to 2005 where he served as chief technology officer and vice president research and development. He was also senior director pharmacology and toxicology at EPIX Medical Inc. from 1997 to 2000 and director of therapeutic development at Creative Biomolecules from 1993 to 1997. Prior to his career in industry Dr. Chan held a number of academic appointments most recently as associate director of the Purdue University Cancer Center and a tenured professor at Purdue University and Indiana University. He is a member of several NIH Study Sections and consults for the U.S. Department of Defense on their prostate and breast cancer research programs. Dr. Chan received his doctorate in pharmacology/toxicology from the University of British Columbia and was a postdoctoral fellow in hematology/oncology at the Cancer Center of the University of California San Diego School of Medicine. | 